White William B, Lacourciere Yves, Gana Theophilus, Pascual Maria G, Smith David H, Albert Kenneth S
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Conn 06030-3940, USA.
Am Heart J. 2004 Oct;148(4):628-34. doi: 10.1016/j.ahj.2004.07.008.
Therapeutic agents for the treatment of hypertension may differ in their efficacy during the early morning period, a time when both morbid and mortal cardiovascular events are increased compared to other times of the day.
We studied the effects of a graded-release delivery system of diltiazem (diltiazem HCL extended release tablets) versus ramipril, both dosed at bedtime, on blood pressure (BP), heart rate, and the heart rate-systolic BP product during the first 4 hours after awakening in a double-blind, titration-to-effect trial. There were 261 men and women enrolled in the trial with an untreated sitting diastolic BP of 90 to 109 mm Hg and ambulatory daytime diastolic BP of 85 to 109 mm Hg. Patients were randomized to either diltiazem extended release (ER) tablets each evening (240 mg titrated to 360 mg and to 540 mg) or ramipril each evening (5 mg titrated to 10 mg and to 20 mg). Early morning assessments of BP, heart rate, and the heart rate-systolic BP product were performed using 24-hour ambulatory recordings after 10 weeks of therapy.
In each therapeutic group, 76% of patients were titrated to the highest possible dose. After 10 weeks of treatment, reductions in early morning BP by diltiazem ER tablets were significantly greater (-18/-15 mm Hg) than reductions by ramipril (-13/-8 mmHg, P <.005 for systolic BP and P <.001 for diastolic BP). Diltiazem ER tablets also led to greater reductions in morning heart rate and the heart rate-pressure product compared to ramipril. Reductions in mean 24-hour diastolic BP, heart rate, and the rate-pressure product were greater in patients treated with diltiazem ER tablets compared to ramipril, while reductions in 24-hour systolic BP were similar in each group. The observed adverse effects were not serious and incidences were similar for the 2 treatment groups.
These data demonstrate that bedtime administration of diltiazem ER, an agent designed to parallel the circadian rhythm of BP and heart rate, led to significantly greater early morning hemodynamic effects compared to the angiotensin-converting enzyme inhibitor ramipril, also dosed in the evening.
用于治疗高血压的治疗药物在清晨时段的疗效可能有所不同,与一天中的其他时段相比,此时心血管疾病的发病和死亡事件均有所增加。
在一项双盲、剂量滴定至有效剂量的试验中,我们研究了睡前服用的缓释地尔硫䓬(盐酸地尔硫䓬缓释片)与雷米普利对觉醒后最初4小时内血压(BP)、心率以及心率-收缩压乘积的影响。共有261名男性和女性参与该试验,其未治疗时的坐位舒张压为90至109 mmHg,日间动态舒张压为85至109 mmHg。患者被随机分为每晚服用地尔硫䓬缓释(ER)片(240 mg滴定至360 mg和540 mg)或每晚服用雷米普利(5 mg滴定至10 mg和20 mg)。治疗10周后,使用24小时动态记录进行清晨血压、心率以及心率-收缩压乘积的评估。
在每个治疗组中,76%的患者被滴定至最高可能剂量。治疗10周后,地尔硫䓬ER片使清晨血压的降低幅度(-18/-15 mmHg)显著大于雷米普利(-13/-8 mmHg,收缩压P <.005,舒张压P <.001)。与雷米普利相比,地尔硫䓬ER片还使清晨心率和心率-血压乘积的降低幅度更大。与雷米普利相比,服用地尔硫䓬ER片的患者24小时平均舒张压、心率以及心率-血压乘积的降低幅度更大,而两组24小时收缩压的降低幅度相似。观察到的不良反应并不严重,两个治疗组的发生率相似。
这些数据表明,与同样在晚上给药的血管紧张素转换酶抑制剂雷米普利相比,睡前服用旨在与血压和心率昼夜节律同步的地尔硫䓬ER,其清晨血流动力学效应显著更大。